Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

423803

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS Protect
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many investigation NHS Protect have commenced into directors of NHS Trusts (a) nationally and (b) in Yorkshire in the last 18 months; and how many of those investigations are ongoing.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	13485
answer	answer is ministerial correction date of answer 29/10/2015 answer text <p>In the last 18 months NHS Protect has commenced three investigations into directors of National Health Service trusts. All three investigations are ongoing and further information cannot be given at this time.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2015 17:29:11 answering member 4020 label Biography information for George Freeman
tabling member	1533 label Biography information for Dame Diana Johnson

423804

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS Protect
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the average time is for NHS Protect to complete an investigation.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	13484
answer	answer is ministerial correction date of answer 29/10/2015 answer text <p>This information is not held centrally and could only be obtained at disproportionate cost.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2015 17:30:23 answering member 4020 label Biography information for George Freeman
tabling member	1533 label Biography information for Dame Diana Johnson

423837

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Home Care Services: Living Wage
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with home social care providers on the effect of the national living wage on the financial position of those providers; and if he will make a statement.
tabling member constituency	Harrow West
tabling member printed	Gareth Thomas
uin	13500
answer	answer is ministerial correction date of answer 29/10/2015 answer text <p>I refer the hon. Member to the answer I gave on 21 October 2015 to Question<a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2015-10-13/11609/" target="_blank"> 11609</a>.</p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 29/10/2015 17:25:32 answering member 1201 label Biography information for Alistair Burt
tabling member	177 label Biography information for Gareth Thomas

423864

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Crohn's Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress has been made on tackling Crohn's disease.
tabling member constituency	South Suffolk
tabling member printed	James Cartlidge
uin	13375
answer	answer is ministerial correction date of answer 29/10/2015 answer text <br /><p>Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.</p><br /><p>Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.</p><br /><p>In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.</p><br /><p>In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.</p><br /><p>NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance <em>Crohn’s Disease Management in Adults, Children and Young People</em> in October 2012, and <em>Ulcerative Colitis</em> <em>Management in Adults, Children and Young People</em> , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 13299 13300 question first answered 29/10/2015 17:23:06 answering member 4020 label Biography information for George Freeman
tabling member	4519 label Biography information for James Cartlidge

423943

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Inflammatory Bowel Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of people with both ulcerative colitis and Crohn's disease who have benefitted from the use of vedolizumab as a treatment option since February 2015; and what the cost of this treatment has been in that period.
tabling member constituency	Brigg and Goole
tabling member printed	Andrew Percy
uin	13299
answer	answer is ministerial correction date of answer 29/10/2015 answer text <br /><p>Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.</p><br /><p>Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.</p><br /><p>In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.</p><br /><p>In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.</p><br /><p>NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance <em>Crohn’s Disease Management in Adults, Children and Young People</em> in October 2012, and <em>Ulcerative Colitis</em> <em>Management in Adults, Children and Young People</em> , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 13300 13375 question first answered 29/10/2015 17:23:06 answering member 4020 label Biography information for George Freeman
tabling member	3939 label Biography information for Andrew Percy

423944

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Crohn's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment his Department has made of the effectiveness of vedolizumab as a treatment for Crohn's disease.
tabling member constituency	Brigg and Goole
tabling member printed	Andrew Percy
uin	13300
answer	answer is ministerial correction date of answer 29/10/2015 answer text <br /><p>Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.</p><br /><p>Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.</p><br /><p>In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.</p><br /><p>In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.</p><br /><p>NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance <em>Crohn’s Disease Management in Adults, Children and Young People</em> in October 2012, and <em>Ulcerative Colitis</em> <em>Management in Adults, Children and Young People</em> , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 13299 13375 question first answered 29/10/2015 17:23:06 answering member 4020 label Biography information for George Freeman
tabling member	3939 label Biography information for Andrew Percy

423952

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the effectiveness of the (a) Bendamustine and (b) Ibrutinib drugs in treating cancer; and if he will make a statement.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	13444
answer	answer is ministerial correction date of answer 29/10/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body which makes decisions on the clinical and cost effectiveness of products based on a thorough assessment of the best available evidence and in consultation with stakeholders. National Health Service commissioners are required to fund drugs and treatments recommended by NICE technology appraisals.</p><br /><p>Bendamustine (Levact) is recommended by NICE as a possible treatment for some people with chronic lymphocytic leukaemia of Binet stage B or C.</p><br /><p>NICE is currently appraising ibrutinib (Imbruvica) for the treatment of (i) chronic lymphocytic leukaemia (NICE’s final guidance is expected in June 2016) and (ii) mantle cell, relapsed, refractory lymphoma (NICE’s final guidance is expected in December 2016).</p><br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2015 17:31:39 answering member 4020 label Biography information for George Freeman
tabling member	253 label Biography information for Mr Laurence Robertson

423565

registered interest
date	23/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS Trusts: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what new performance target for Trusts and Foundation Trusts has been introduced since May 2010; and which new performance targets he plans to introduce for those bodies over the next five years.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	13250
answer	answer is ministerial correction date of answer 28/10/2015 answer text <p>A number of operational standards related to access and waiting times have been introduced or amended since May 2010. All the changes were based on recommendations from clinical experts.</p><br /><p>As part of our response to the Independent Cancer Taskforce’s report, we have announced our commitment that – by 2020 – 95% of National Health Service patients will be given a definitive cancer diagnosis or the all clear within 28 days of being referred by a general practitioner. This will be underpinned by investment - expected to be £300 million more in diagnostics a year by 2020.</p><p><strong></strong></p><p>We are also introducing the first waiting times standards specifically for mental health so that, from April 2016:</p><br /><p>- 75% of people will be referred to the Improving Access to Psychological Therapies programme within six weeks, with 95% of people being referred within 18 weeks; and</p><p>- 50% of people experiencing a first episode of psychosis will be treated within two weeks.</p><br /> answering member constituency Battersea answering member printed Jane Ellison question first answered 28/10/2015 17:29:53 answering member 3918 label Biography information for Jane Ellison
tabling member	4418 label Biography information for Justin Madders

423566

registered interest
date	23/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Department of Health: Public Expenditure
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make it his policy to maintain ringfencing for total NHS funding in the Autumn Statement.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	13249
answer	answer is ministerial correction date of answer 28/10/2015 answer text <p>The Government has protected the funding the National Health Service receives and increased the Department’s budget in real terms year on year. There is no plan to change this, fulfilling the Government’s manifesto commitment. By 2020-21, the Government will increase funding for the NHS by £10 billion a year in real terms compared to 2014-15 to support the implementation of the NHS’s own plan - the NHS Five Year Forward View - to transform services across the country.</p><p><strong></strong></p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 28/10/2015 17:01:45 answering member 1201 label Biography information for Alistair Burt
tabling member	4418 label Biography information for Justin Madders

423570

registered interest
date	23/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many training places in the Improving Access to Psychological Therapies service there were in each of the last five years.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	13214
answer	answer is ministerial correction date of answer 28/10/2015 answer text <p>There were 756 training places commissioned for improving access to psychological therapies (IAPT) programmes in 2014/15. In addition 509 trainees attended Child and Young People’s (CYP) IAPT courses in 2014/15.</p><br /><p>The following table contains an aggregate of the number of training places that have been commissioned in each of the last four financial years for the IAPT programmes. Comparable information relating to the IAPT programmes is not held centrally for the 2011/12 financial year.</p><br /><table><tbody><tr><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td></tr><tr><td><p>IAPT training places commissioned</p></td><td><p>634</p></td><td><p>859</p></td><td><p>756</p></td><td><p>946</p></td></tr></tbody></table><p><em>Source: </em>multi professional education and training budget monitoring returns</p><br /><p>The following table details the number of trainees attending CYP IAPT courses per year of the programme in the last five years.</p><br /><table><tbody><tr><td><p><br></p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td></tr><tr><td><p>Trainee Therapist</p></td><td><p>97</p></td><td><p>142</p></td><td><p>252</p></td><td><p>372</p></td><td><p>537</p></td></tr><tr><td><p>Supervisor <br></p></td><td><p>30</p></td><td><p>45</p></td><td><p>88</p></td><td><p>86</p></td><td><p>113</p></td></tr><tr><td><p>Service Lead</p></td><td><p>35</p></td><td><p>48</p></td><td><p>73</p></td><td><p>51</p></td><td><p>114</p></td></tr><tr><td><p>TOTAL <br></p></td><td><p>162</p></td><td><p>235</p></td><td><p>413</p></td><td><p>509</p></td><td><p>764</p></td></tr></tbody></table><p><em>Source: </em>NHS England</p><p><strong></strong></p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 13216 question first answered 28/10/2015 17:03:52 answering member 1201 label Biography information for Alistair Burt
tabling member	4036 label Biography information for Luciana Berger